Abstract
Dimethyl fumarate (DMF) promotes an IL-17Alow IFN-γlow IL-4+ CD4+ T cell phenotype. Adoptive transfer of in vitro DMF-treated myelin peptide-reactive IL-17Alow IFN-γlow IL-4+ CD4+ T cells prior to immunization for EAE reduces the severity of encephalomyelitis. This beneficial effect of transferred DMF-treated CD4+ T cells requires an early in vivo recall.
Keywords:
Dimethyl fumarate; EAE; Immunotherapy; T cell vaccine; Th17 cells.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adoptive Transfer
-
Animals
-
CD4-Positive T-Lymphocytes / immunology*
-
CD4-Positive T-Lymphocytes / transplantation
-
Dimethyl Fumarate / pharmacology*
-
Encephalomyelitis, Autoimmune, Experimental / immunology*
-
Encephalomyelitis, Autoimmune, Experimental / prevention & control*
-
Immunosuppressive Agents / pharmacology*
-
Interferon-gamma / biosynthesis
-
Interferon-gamma / immunology*
-
Interleukin-10 / biosynthesis
-
Interleukin-10 / immunology
-
Interleukin-17 / biosynthesis
-
Interleukin-17 / immunology
-
Interleukin-4 / biosynthesis
-
Interleukin-4 / immunology*
-
Mice
-
Th1 Cells / immunology
-
Th17 Cells / immunology*
-
Th2 Cells / immunology
Substances
-
IFNG protein, mouse
-
IL10 protein, mouse
-
Il17a protein, mouse
-
Immunosuppressive Agents
-
Interleukin-17
-
Interleukin-10
-
Interleukin-4
-
Interferon-gamma
-
Dimethyl Fumarate